Term
What are Beclomethasone's side effects? |
|
Definition
Fungal infection in the mouth. Minimal systemic effects |
|
|
Term
Beclomethasone's trade names |
|
Definition
|
|
Term
Beclomethasone's classification |
|
Definition
Steroidal Antiinflammatory |
|
|
Term
|
Definition
MDI .252 mg (0.084 mg/actuation) |
|
|
Term
Beclomethasone's instruction |
|
Definition
Rinse mouth and/or use spacer |
|
|
Term
Beclomthasone dipropionate's classification |
|
Definition
Steroidal Antiinflammatory |
|
|
Term
Beclomthasone dipropionate's dosage |
|
Definition
|
|
Term
Beclomthasone dipropionate's instruction |
|
Definition
Rinse mouth and/or use spacer |
|
|
Term
Beclomthasone dipropionate's side effects |
|
Definition
Fungal infections in mouth. Minimal systemic effects |
|
|
Term
Beclomthasone dipropionate's trade name |
|
Definition
|
|
Term
Triamcinolone’s side effects? |
|
Definition
Fungal infection in mouth. Minimal systemic effects |
|
|
Term
Triamcinolone's classification? |
|
Definition
Steroidal Antiinflammatory |
|
|
Term
|
Definition
MDI 200 mcg (42 mcg/actuation) |
|
|
Term
Triamcinolone's instruction? |
|
Definition
Rinse mouth and/or use spacer |
|
|
Term
Triamcinolone's trade name |
|
Definition
|
|
Term
Flunisolide's instructions |
|
Definition
Rinse mouth and/or use spacer |
|
|
Term
Flunisolide's side effects |
|
Definition
Fungal infections in mouth. Minimal systemic effects |
|
|
Term
|
Definition
|
|
Term
Flunisolide's classification |
|
Definition
Steroidal Antiinflammatory |
|
|
Term
|
Definition
MDI 500 mcg (250 mcg/actuation) |
|
|
Term
Fluticasone propionate's instructions? |
|
Definition
Rinse mouth and/or use spacer |
|
|
Term
Fluticasone propionate's receptor sites? |
|
Definition
|
|
Term
Fluticasone propionate's side effects? |
|
Definition
Increased HR, tremors, nervousness, thrush |
|
|
Term
Fluticasone propionate's side effects? |
|
Definition
Fungal infections in the mouth. Minimal systemic effects |
|
|
Term
Fluticasone propionate's classification? |
|
Definition
Combo longlasting adrenergic bronchodilator and steroid |
|
|
Term
Fluticasone propionate's classification? |
|
Definition
Steroidal Antiinflammatory |
|
|
Term
Fluticasone propionate's dosage? |
|
Definition
MDI/DPI BID (2x/day) 125/25 mcg or 250/25 mcg |
|
|
Term
Fluticasone propionate's generic names |
|
Definition
|
|
Term
Fluticasone propionate's trade name? |
|
Definition
|
|
Term
Budesonide's Receptor sites? |
|
Definition
|
|
Term
Budesonide's side effects? |
|
Definition
Increased HR, tremor, nervousness, thrush |
|
|
Term
Budesonide's side effects? |
|
Definition
Fungal infections in mouth |
|
|
Term
What is Budesonide's classification? |
|
Definition
Combination longacting adrenergic bronchodilator and steroid |
|
|
Term
What is Budesonide's dosage? |
|
Definition
MDI 80/4.5 ug and 160/4.5 ug Budesonide and Formoterol 2 puffs BID (MDI = Metered Dose Inhaler) |
|
|
Term
What is Budesonide's dosage? |
|
Definition
|
|
Term
What is Budesonide's other generic name? |
|
Definition
Formoterol fumarate dihydrate |
|
|
Term
What is Budesonide's trade name? |
|
Definition
|
|
Term
What is Budesonide's trade name? |
|
Definition
|
|
Term
What are Fluticasone propionate's instructions? |
|
Definition
Rinse mouth and/or use spacer |
|
|
Term
What are Fluticasone propionate's receptor sites? |
|
Definition
Beta 1, Beta 2 (Hint: Beta 1 (one heart), Beta 2 (two lungs)) Have patient rinse mouth |
|
|
Term
What are Fluticasone propionate's side effects? |
|
Definition
Increased HR, tremors, nervousness, thrush |
|
|
Term
What is Fluticasone propionate's classification? |
|
Definition
Combination longlasting adrenergic bronchodilator and steroid |
|
|
Term
What is Fluticasone propionate's classification? |
|
Definition
Steroidal Antiinflammatory |
|
|
Term
What is Fluticasone propionate's dosage? |
|
Definition
MDI/DPI BID (2x/day) 2 dosage strengths 125/25 mcg and 250/25 mcg |
|
|
Term
What is Fluticasone propionate's other generic name? |
|
Definition
|
|
Term
What is Fluticasone propionate's trade name? |
|
Definition
|
|
Term
What are Cromolyn sodium's Side effects? |
|
Definition
Cough and bronchospasm in powder form only |
|
|
Term
What is Cromolyn sodium's 1st trade name? |
|
Definition
|
|
Term
What is Cromolyn sodium's 2nd trade name? |
|
Definition
|
|
Term
What is Cromolyn sodium's classification? |
|
Definition
NonSteroidal AntiInflammatory (NSAID) |
|
|
Term
What is Cromolyn sodium's Dosage? |
|
Definition
20 mg MDI 1600 mcg (800 mcg/actuation)(MDI = Metered Dose Inhaler) |
|
|
Term
What is Cromolyn sodium's Instructions? |
|
Definition
2 puffs 1015 minutes (not >60) before exercise; cold, dry air or environmental agents for acute |
|
|
Term
What is Nedocromil sodium's classification? |
|
Definition
Non Steroidal Anti Inflammatory (NSAID) |
|
|
Term
What is Nedocromil sodium's dosage? |
|
Definition
MDI 3.5 mg QID (1.75 mg/actuation)(MDI = Metered Dose Inhaler)(QID = Four times a day) |
|
|
Term
What is Nedocromil sodium's instruction? |
|
Definition
Must be taken regularly to achieve benefit |
|
|
Term
What is Nedocromil sodium's side effect? |
|
Definition
|
|
Term
What is Nedocromil sodium's trade name? |
|
Definition
|
|
Term
What are Pentamindine’s side effects? |
|
Definition
|
|
Term
What is Pentamindine's classification? |
|
Definition
|
|
Term
What is Pentamindine's dosage? |
|
Definition
600 mg once/day using the Respiguard Nebulizer. with 6 ml of sterile water. Run at 8 LPM |
|
|
Term
What is Pentamindine's trade name? |
|
Definition
|
|
Term
What is Tobramycin's classification? |
|
Definition
|
|
Term
What is Tobramycin's dosage? |
|
Definition
|
|
Term
What is Tobramycin's instruction? |
|
Definition
Do not mix with other meds! |
|
|
Term
What is Tobramycin's trade name? |
|
Definition
|
|
Term
inflammation is mediated by |
|
Definition
|
|
Term
Side Effects Seen With Systemic Administration of Corticosteroids |
|
Definition
• Hypothalamic–pituitary–adrenal suppression • Immunosuppression • Psychiatric reactions • Cataract formation • Myopathy of skeletal muscle • Osteoporosis • Peptic ulcer • Fluid retention • Hypertension • Increased white blood cell count • Dermatological changes • Growth restriction • Increased glucose levels |
|
|
Term
|
Definition
Oropharyngeal fungal infections |
|
|
Term
|
Definition
|
|
Term
|
Definition
Cough, bronchoconstriction |
|
|
Term
HPA suppression (minimal, dose dependent) |
|
Definition
Incorrect use of MDI (inadequate dose) |
|
|
Term
eosinophils predominate in _______ neutrophils are mostly seen in ____ |
|
Definition
asthma COPD Patient with stable COPD should not be given systemic corticosteroids |
|
|
Term
Three subgroups of agents are included in the nonsteroidal antiasthma group: |
|
Definition
cromolyn-like drugs (mast cell stabilizers) antileukotrienes (anti-LTs) monoclonal antibodies. |
|
|
Term
The general indication for clinical use of nonsteroidal antiasthma agents described in this chapter is .... |
|
Definition
prophylactic management (control) of mild persistent asthma |
|
|
Term
All of the nonsteroidal antiasthma drugs described in this chapter are _____, not ______, and are used in asthma requiring ________________ |
|
Definition
controllers relievers antiinflammatory drug therapy |
|
|
Term
A sensitized mast cell fails to degranulate after challenge when ________ |
|
Definition
pretreated with cromolyn sodium |
|
|
Term
|
Definition
(PCP) Pneumocystis pneumonia |
|
|
Term
Inhaled tobramycin used for management of ______ infections in patients with cystic fibrosis. |
|
Definition
Pseudomonas aeruginosa infections in patients with cystic fibrosis. Zanamivir is an inhaled antiviral agent used to treat influenza. |
|
|
Term
indication for Aerosolized Pentamidine |
|
Definition
Pentamidine by inhalation is indicated for the prevention of PCP in high-risk HIV–infected patients who have a history of one or more episodes of PCP or a peripheral CD4+ (T4 helper cell) lymphocyte count of 200/mm3 or less. |
|
|
Term
Indication for Aerosolized Ribavirin |
|
Definition
in infant respiratory syncytial virus (RSV). |
|
|
Term
aerosolized pentamidine must be given via |
|
Definition
|
|
Term
mode of action of pentamidine |
|
Definition
|
|
Term
Side Effects With Parenteral Pentamidine |
|
Definition
Pain, swelling, and abscess formation at the site of injection, with intramuscular administration |
|
|
Term
Side Effects With Aerosol Administration. Side effects with aerosol administration can be differentiated into local airway effects and systemic effects. Local airway effects with aerosol administration have included the following: |
|
Definition
Cough and bronchial irritation in 36% of patients in one study3 Shortness of breath Bad taste (bitter or burning) of the aerosol impacting in the oropharynx Bronchospasm and wheezing in 11% of patients3 Spontaneous pneumothoraces13 In addition, the following systemic reactions have occurred with aerosolized pentamidine: Conjunctivitis Rash Neutropenia Pancreatitis14 Renal insufficiency Dysglycemia (hypoglycemia and diabetes) Digital necrosis in both feet15 Appearance of extrapulmonary P. carinii infection |
|
|
Term
Use of a β-adrenergic bronchodilator before inhaling aerosolized pentamidine can |
|
Definition
reduce or prevent local airway reaction, including reduction of coughing or wheezing. |
|
|
Term
Ribavirin (Virazole) is classified as an antiviral drug; it is active against RSV, influenza viruses, and herpes simplex virus. |
|
Definition
|
|
Term
virostatic - stops it from reproducing |
|
Definition
virostatic - stops it from reproducing |
|
|
Term
Infection with RSV in children results in either bronchiolitis or pneumonia. |
|
Definition
Infection with RSV in children results in either bronchiolitis or pneumonia. |
|
|
Term
Respiratory syncytial virus (RSV) can cause bronchiolitis and pneumonia. |
|
Definition
Respiratory syncytial virus (RSV) can cause bronchiolitis and pneumonia. |
|
|
Term
Ribavirin is given as a 20-mg/ml solution, which is administered by nebulizer (SPAG-2) for 12 to 18 hours per day, for a minimum of 3 days and not more than 7 days. |
|
Definition
Ribavirin is given as a 20-mg/ml solution, which is administered by nebulizer (SPAG-2) for 12 to 18 hours per day, for a minimum of 3 days and not more than 7 days. |
|
|
Term
|
Definition
|
|
Term
The use of TOBI is intended to manage chronic infection with P. aeruginosa in cystic fibrosis, as follows: |
|
Definition
Treat or prevent early colonization with P. aeruginosa |
|
|
Term
|
Definition
for those 6 years or older 300 mg 2 x day 12 hours apart (min. 6 hours apart) 28 days on/28 off |
|
|
Term
Patients should be instructed not to mix dornase alfa or any other drug with tobramycin in the nebulizer. |
|
Definition
|
|
Term
|
Definition
Ototoxicity (auditory and vestibular) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Nonsignificant increase in bacterial resistance |
|
|
Term
|
Definition
Zanamivir (Relenza) is antiviral for treatment of uncomplicated influenza illness (as DPI) in adults and children over 5, during first 2 days of infection. |
|
|